The Department of Justice announced that three pharmaceutical companies — Jazz Pharmaceuticals (JAZZ), Lundbeck (HLUYY), and Alexion Pharmaceuticals (ALXN) – have agreed to pay a total of $122.6M to resolve allegations that they each violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical Program copays for their own products, through purportedly independent foundations that the companies used as mere conduits. Jazz and Lundbeck each entered five-year corporate integrity agreements, or CIAs, with OIG as part of their respective settlements. The CIAs require the companies to implement measures, controls, and monitoring designed to promote independence from any patient assistance programs to which they donate. In addition, the companies agreed to implement risk assessment programs and to obtain compliance-related certifications from company executives and board members.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.